MedTrace Logo

Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis

NCT00812045 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2009-05-06

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of AZD1236 in patients with cystic fibrosis (CF) on inflammatory biomarkers in induced sputum, after a treatment period of 4 weeks.

Conditions

Interventions

DRUG

AZD1236

Oral tablet, 75 mg twice daily during 4 weeks

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Andrew J Lockton, MD · AstraZeneca R&D Charnwood

  • Shawn Aaron, MD · The Ottawa Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Completion
2010-08-31

Countries

  • Canada
  • Netherlands
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812045 on ClinicalTrials.gov